Compare WYETH LTD with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs AUROBINDO PHARMA - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD AUROBINDO PHARMA WYETH LTD/
AUROBINDO PHARMA
 
P/E (TTM) x 27.7 14.7 188.8% View Chart
P/BV x 5.3 3.2 167.7% View Chart
Dividend Yield % 1.3 0.4 324.4%  

Financials

 WYETH LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
AUROBINDO PHARMA
Mar-18
WYETH LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,044809 129.1%   
Low Rs818504 162.3%   
Sales per share (Unadj.) Rs298.6281.1 106.2%  
Earnings per share (Unadj.) Rs57.241.4 138.4%  
Cash flow per share (Unadj.) Rs58.450.9 114.8%  
Dividends per share (Unadj.) Rs17.002.50 680.0%  
Dividend yield (eoy) %1.80.4 479.4%  
Book value per share (Unadj.) Rs249.5199.4 125.1%  
Shares outstanding (eoy) m22.72585.88 3.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.12.3 133.5%   
Avg P/E ratio x16.315.9 102.5%  
P/CF ratio (eoy) x15.912.9 123.6%  
Price / Book Value ratio x3.73.3 113.4%  
Dividend payout %29.76.0 491.3%   
Avg Mkt Cap Rs m21,157384,630 5.5%   
No. of employees `0000.517.3 2.8%   
Total wages/salary Rs m40021,308 1.9%   
Avg. sales/employee Rs Th13,787.49,500.7 145.1%   
Avg. wages/employee Rs Th813.01,229.4 66.1%   
Avg. net profit/employee Rs Th2,643.31,397.9 189.1%   
INCOME DATA
Net Sales Rs m6,783164,666 4.1%  
Other income Rs m3531,020 34.6%   
Total revenues Rs m7,136165,686 4.3%   
Gross profit Rs m1,61737,718 4.3%  
Depreciation Rs m275,580 0.5%   
Interest Rs m6777 0.7%   
Profit before tax Rs m1,93832,380 6.0%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6328,183 7.7%   
Profit after tax Rs m1,30124,229 5.4%  
Gross profit margin %23.822.9 104.1%  
Effective tax rate %32.625.3 129.1%   
Net profit margin %19.214.7 130.3%  
BALANCE SHEET DATA
Current assets Rs m6,984121,878 5.7%   
Current liabilities Rs m2,05686,806 2.4%   
Net working cap to sales %72.621.3 341.1%  
Current ratio x3.41.4 241.9%  
Inventory Days Days99130 76.4%  
Debtors Days Days2468 35.0%  
Net fixed assets Rs m24481,037 0.3%   
Share capital Rs m227586 38.8%   
"Free" reserves Rs m5,441116,218 4.7%   
Net worth Rs m5,668116,804 4.9%   
Long term debt Rs m254,512 0.6%   
Total assets Rs m7,901211,052 3.7%  
Interest coverage x353.342.7 828.2%   
Debt to equity ratio x00 11.4%  
Sales to assets ratio x0.90.8 110.0%   
Return on assets %16.511.8 139.5%  
Return on equity %22.920.7 110.6%  
Return on capital %34.027.4 124.4%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1580,727 0.0%   
Fx outflow Rs m2,67734,700 7.7%   
Net fx Rs m-2,66246,027 -5.8%   
CASH FLOW
From Operations Rs m92319,548 4.7%  
From Investments Rs m317-19,570 -1.6%  
From Financial Activity Rs m-4818,642 -5.6%  
Net Cashflow Rs m7598,922 8.5%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 8.0 142.1%  
FIIs % 7.2 27.7 26.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 10.2 298.0%  
Shareholders   21,978 69,601 31.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare WYETH LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - NOVARTIS COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS